目的 探討肺力咳膠囊聯(lián)合阿莫西林治療急性氣管-支氣管炎的臨床效果。方法 選取2016年6月-2019年6月北京市東城區(qū)第一人民醫(yī)院收治的96例急性氣管-支氣管炎，隨機(jī)分為對(duì)照組和治療組，每組各48例。對(duì)照組口服阿莫西林膠囊，0.5 g/次，3次/d。治療組在對(duì)照組治療基礎(chǔ)上口服肺力咳膠囊，3粒/次，3次/d。兩組均連續(xù)治療2周。比較兩組的臨床療效，比較兩組典型癥狀的消失時(shí)間、白細(xì)胞計(jì)數(shù)（WBC）、中性粒細(xì)胞百分率（NEUT%）異常情況、血清腫瘤壞死因子（TNF）-α、白介素（IL）-8、超敏C反應(yīng)蛋白（hs-CRP）。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別是83.3%、95.8%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組在典型癥狀咳嗽、咳痰的消失時(shí)間上均顯著短于對(duì)照組（P<0.05）。兩組治療后WBC、NETU%異常率均顯著低于治療前（P<0.05）；但治療后，治療組血象情況優(yōu)于對(duì)照組同期（P<0.05）。兩組治療后血清各項(xiàng)炎癥標(biāo)志物（TNF-α、IL-8、hs-CRP）水平均顯著低于治療前（P<0.05），且治療組下降更顯著（P<0.05）。結(jié)論 肺力咳膠囊聯(lián)合阿莫西林治療急性氣管-支氣管炎整體療效良好，可迅速減輕患者癥狀，恢復(fù)血象，拮抗機(jī)體炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Feilike Capsules combined with amoxicillin in treatment of acute tracheal-bronchitis. Methods Ninety-six patients with acute tracheal-bronchitis admitted to the First People's Hospital of Dongcheng District in Beijing from June 2016 to June 2019 were randomly divided into control group (n=48) and treatment group (n=48). The control group was po administered with Amoxicillin Capsules, 0.5 g/time, three times daily. The treatment group was po administered with Feilike Capsules on the basis of the control group, 3 grains/time, three times daily. All patients were treated for 2 weeks. The clinical efficacy of the two groups was compared. The disappearance time of typical symptoms, white blood cell count (WBC), abnormal percentage of neutrophils (NEUT%), tumor necrosis factor (TNF)-α and interleukin (IL)-8, high-sensitivity C-reactive protein (hs-CRP) in two groups were compared. Results The total effective rate in the control and treatment groupswas 83.3% and 95.8%, respectively, and there were differences between two groups (P<0.05). In the disappearance time of typical symptoms of cough and cough, the treatment group was significantly shorter than the control group (P<0.05). The WBC and NETU% abnormal rates were significantly lower in the two groups than before treatment (P<0.05). However, after treatment, the blood levels in the treatment group were better than those in the control group (P<0.05). The concentrations of serum inflammatory markers (TNF-α, IL-8, hs-CRP) in the two groups were significantly lower than those before treatment (P<0.05), and the treatment group decreased more significantly (P<0.05). Conclusion Feilixie Capsule combined with amoxicillin has overall effect in the treatment of acute tracheal-bronchitis, and can help to quickly alleviate the symptoms of patients, improve peripheral blood, down-regulate the expression level of relevant inflammatory markers in the blood, which has a certain clinical application value.

R974